[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620734":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":26,"studyPopulation":26,"armGroups":33,"interventions":40,"overallOfficials":45,"centralContacts":49,"locations":56,"responsibleParty":74,"collaborators":26,"id":76,"slug":26,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":26,"enrollmentInfo":85,"targetDuration":26,"studyType":88,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":58,"whyStopped":26,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.","Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy.\n\nLong responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.","Through study completion, an average of 1 year",[14,17,20,23],{"measure":15,"description":16,"timeFrame":12},"Phenotypic criteria differences between refactory patients and long responder patients","Phenotypic criteria will include BMI, personal history and family history",{"measure":18,"description":19,"timeFrame":12},"Clinical criteria differences between refactory patients and long responder patients","Clinical criteria will include age at diagnosis, FIGO stage, initial PCI score, CCO score",{"measure":21,"description":22,"timeFrame":12},"Biological criteria difference between refactory patients and long responder patients","Biological criteria include CA-125",{"measure":24,"description":25,"timeFrame":12},"Histological criteria differences between refactory patient and long responder patients","Histological criteria include histological type, presence of emboli, Ki-67, RO, RP, WT1, PAX8, PD-L1, CD8, p53, HER2",null,{"allocation":28,"interventionModel":29,"interventionModelDescription":30,"primaryPurpose":6,"observationalModel":26,"timePerspective":26,"maskingInfo":31},"NA","SINGLE_GROUP","It is a single-centre study with a prospective part (living patients) and a retrospective part (deceased patients) involving data collection via the patient's medical software. A molecular analysis on histological blocks taken at the time of diagnosis will be carried out as part of the study. This analysis may potentially generate new genomic data to classify patients with ovarian cancer. Could result in the incidental discovery of abnormalities, which may eventually modify the management of the patient, notably her monitoring and screening for other pathologies.\n\nNo additional sampling will be carried out as part of the study.",{"masking":32,"maskingDescription":26,"whoMasked":26},"NONE",[34],{"label":35,"type":36,"description":37,"interventionNames":38},"long-term responders","EXPERIMENTAL","molecular analysis on histological blocks",[39],"Genetic: molecular analysis",[41],{"type":42,"name":43,"description":37,"armGroupLabels":44,"otherNames":26},"GENETIC","molecular analysis",[35],[46],{"name":47,"affiliation":5,"role":48},"Tressie HERRMANN, MD","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":54,"email":55},"Judith PASSILDAS JAHANMOHAN, PhD","CONTACT","0463663337","+33","judith.passildas@clermont.unicancer.fr",[57],{"facility":5,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Clermont-Ferrand","PUY DE DOME","63001","France","FR",{"type":65,"coordinates":66},"Point",[67,68],3.08682,45.77969,{"lat":68,"lon":67},[71,72],{"name":51,"role":52,"phone":26,"phoneExt":26,"email":55},{"name":73,"role":48,"phone":26,"phoneExt":26,"email":26},"HERRMANN Tressie, MD",{"type":75,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100620734",false,"NCT07361471","Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy","Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy.","ORTRAI","Inclusion Criteria:\n\n* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.\n* Corresponding to one of the two groups below:\n\n  * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.\n  * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment\n* Affiliation to a social security scheme\n* Patient who signed the genetic consent form\n\nExclusion Criteria:\n\n* Minor patient\n* Pregnant patient\n* Patient under guardianship or conservatorship\n* Patients who object to the collection of their medical\u002Fparamedical data\n* Patient for whom the center does not have biological material for genomic analysis (FFPE block)\n* Patient under administrative, judicial decision or AME (State Medical Aid)","FEMALE","18 Years",{"count":86,"type":87},55,"ESTIMATED","INTERVENTIONAL",[28],"After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.\n\nThe clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.\n\nThe complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.",[92],"Ovarian Cancer",[94,95],"ovarian cancer","long responder","2026-02-18",{"date":98,"type":99},"2026-02-20","ACTUAL",{"date":101,"type":99},"2026-01-22",{"date":103,"type":87},"2027-12-01",{"name":5,"class":6},1]